Last reviewed · How we verify

KX-826-（5%） BID — Competitive Intelligence Brief

KX-826-（5%） BID (KX-826-（5%） BID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical androgen receptor antagonist. Area: Dermatology.

phase 3 Topical androgen receptor antagonist Androgen receptor (AR) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

KX-826-（5%） BID (KX-826-（5%） BID) — Suzhou Kintor Pharmaceutical Inc,. KX-826 is a topical androgen receptor antagonist that inhibits DHT-mediated signaling in hair follicles to treat androgenetic alopecia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
KX-826-（5%） BID TARGET KX-826-（5%） BID Suzhou Kintor Pharmaceutical Inc, phase 3 Topical androgen receptor antagonist Androgen receptor (AR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical androgen receptor antagonist class)

  1. Suzhou Kintor Pharmaceutical Inc, · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KX-826-（5%） BID — Competitive Intelligence Brief. https://druglandscape.com/ci/kx-826-5-bid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: